Voyageur Pharmaceuticals Ltd.

VM

CA92918C1014

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 11:22:42 2024-05-10 am EDT			5-day change	1st Jan Change
0.055 ^CAD	0.00%		+10.00%	-26.67%

Apr. 26	Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended February 29, 2024	CI
Mar. 26	Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended November 30, 2023	CI

Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended February 29, 2024

April 26, 2024 at 05:02 pm EDT

Voyageur Pharmaceuticals Ltd. reported earnings results for the first quarter ended February 29, 2024. For the first quarter, the company reported net loss was CAD 0.328945 million compared to CAD 0.373693 million a year ago.

Latest news about Voyageur Pharmaceuticals Ltd.

Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended February 29, 2024	Apr. 26	CI
Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended November 30, 2023	Mar. 26	CI
Voyageur Pharmaceuticals Ltd. Announces A Significant Advancement in Its Partnership with Rain Cage Carbon Inc	Mar. 13	CI
Voyageur Pharmaceuticals Ltd. and Applied Pharmaceutical Innovation Sign Master Services Agreement	Mar. 04	CI
Voyageur Pharmaceuticals Ltd. announced that it has received CAD 0.4885 million in funding	Feb. 29	CI
Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 0.8 million in funding	Jan. 15	CI
Voyageur Pharmaceuticals Ltd. Announces the Formalization of A Pivotal Sales and Distribution Alliance	Dec. 14	CI
Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023	23-10-30	CI
Voyageur Pharmaceuticals Ltd. Announces Board Changes	23-08-01	CI
Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023	23-07-31	CI
Voyageur Pharmaceuticals Ltd. Announces the Release of the White Paper	23-06-12	CI
Voyageur Pharmaceuticals Ltd. Advances with Environmental Field Work At Frances Creek Project Site for Notice of Work & Quarry Permitting	23-05-31	CI
Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended February 28, 2023	23-04-28	CI
Voyageur Pharmaceuticals Ltd. Completes Comparative Studies of Its SmoothX® Contrast Media Confirming Product Superiority	23-04-06	CI
Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended November 30, 2022	23-03-30	CI
Voyageur Pharmaceuticals Ltd. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
Voyageur Pharmaceuticals Ltd. announced that it has received CAD 1.199949 million in funding	23-01-19	CI
Voyageur Pharmaceuticals Ltd. Announces Canadian Launch of Smoothx Barium Contrast Media & Financing	22-12-08	CI
Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 0.65 million in funding	22-12-07	CI
Voyageur Pharmaceuticals Ltd. Completes Medical Imaging CT Contrast Agent Production Testing and Begins Production Scale-Up of SmoothX	22-11-28	CI
Voyageur Pharmaceuticals Ltd. Completes Design of Carbon Neutral Pharmaceutical Facility on Alberta	22-11-01	CI
Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022	22-10-31	CI
Voyageur Pharmaceuticals’ MOU with Rain Cage Carbon to Develop Fullerene-Based Medical Contrast Agents from Carbon Capture of Hydrocarbon Exhaust Systems	22-10-26	CI
Voyageur Pharmaceuticals Ltd Signs Memorandum of Understanding with Rain Cage Carbon Inc	22-10-24	CI
Voyageur Pharmaceuticals Submits A Notice of Work with the Bc Ministry of Mines, for the Removal of 2,000 Tonnes of Barium Sulfate from its Frances Creek Project	22-09-23	CI

Chart Voyageur Pharmaceuticals Ltd.

Duration

Period

More charts

Company Profile

Voyageur Pharmaceuticals Ltd. is a Canadian company, which develops barium, iodine and carbon active pharmaceutical ingredients. The Company is focused on producing its own barium, iodine and fullerene minerals. The Company, through its subsidiaries, Voyageur Industrial Minerals Ltd. and Voyageur Minerals Inc., is engaged in acquiring, exploring and developing raw materials for pharmaceutical products, primarily in the province of British Columbia, Canada and the state of Utah, United States. Its properties include Jubilee Mountain, Falcon and Paradox Basin. It owns a 100% interest in two barium sulphate (barite) projects, including the Frances Creek and Pedley Mountain property. It holds interests in a high-grade iodine, lithium, and bromine brine project situated in Utah, United States. It owns a 100% interest in two battery mineral projects that is focused on copper/zinc development. Its pipeline products include SmoothX 2.0%, MultiX Thick, MultiX Thin, HDX, LDX, VY-101 and VY-103.

Sector

Pharmaceuticals

Calendar

2024-07-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VOYAGEUR PHARMACEUTICALS LTD.	-26.67%	5.58M
ELI LILLY AND COMPANY	+31.06%	682B
NOVO NORDISK A/S	+30.35%	586B
JOHNSON & JOHNSON	-3.42%	364B
MERCK & CO., INC.	+18.02%	327B
ABBVIE INC.	+4.27%	285B
ASTRAZENECA PLC	+15.53%	240B
NOVARTIS AG	+10.16%	209B
ROCHE HOLDING AG	-8.14%	203B
AMGEN INC.	+8.12%	165B

Other Pharmaceuticals